Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastases.

Molecular cancer therapeutics - 1 Jun 2010

Vallera Daniel A, Oh Seunguk, Chen Hua, Shu Yanqun, Frankel Arthur E

Abstract excerpt

A drug of high potency and reduced immunogenicity is needed to develop a targeted biological drug that when injected systemically can penetrate to malignant B cells. Therefore, a novel deimmunized bispecific ligand-directed toxin targeted by dual high-affinity single-chain Fvs (scFv) spliced to P...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ADP Ribose Transferases
Share to Antibodies, Bispecific
Share to Antigens, CD19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bacterial Toxins

Share to Cell Death

Share to Exotoxins

Share to Mice, SCID

Share to Virulence Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 20530709
DOI: 10.1158/1535-7163.MCT-10-0203
PMCID: PMC2884080

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20530709-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastases.PMID 20530709Read ↗

Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancySemantic proximity Read ↗

A deimmunized bispecific ligand-directed toxin that shows an impressive anti-pancreatic cancer effect in a systemic nude mouse orthotopic model.Semantic proximity Read ↗

Removal of B-cell epitopes for decreasing immunogenicity in recombinant immunotoxin against B-cell malignancies.Semantic proximity Read ↗

Immunotoxins with decreased immunogenicity and improved activity.Semantic proximity Read ↗

Rational design of low immunogenic anti CD25 recombinant immunotoxin for T cell malignancies by elimination of T cell epitopes in PE38.Semantic proximity Read ↗

Mutation-guided therapeutics.Semantic proximity Read ↗

A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity.Semantic proximity Read ↗

HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity.Semantic proximity Read ↗

Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.Semantic proximity Read ↗

Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.Semantic proximity Read ↗

Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A.Semantic proximity Read ↗

Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell VectorSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.